keyword
MENU ▼
Read by QxMD icon Read
search

CVADs

keyword
https://www.readbyqxmd.com/read/29754648/the-cvad-registry-for-percutaneous-temporary-hemodynamic-support-a-prospective-registry-of-impella-mechanical-circulatory-support-use-in-high-risk-pci-cardiogenic-shock-and-decompensated-heart-failure
#1
George W Vetrovec, Mark Anderson, Theodore Schreiber, Jeffrey Popma, William Lombardi, Brijeshwar Maini, Jacob Eifer Moller, Andreas Schäfer, Simon R Dixon, Shelley Hall, E Magnus Ohman, Catalin Mindrescu, Jeffrey Moses, William O'Neill
Management of patients requiring temporary, mechanical hemodynamic support during high- risk percutaneous coronary intervention (PCI) or in cardiogenic shock is rapidly evolving. With the availability of the Impella 2.5, CP, 5.0, LD, and RP percutaneous mechanical circulatory support devices, there is a need for continued surveillance of outcomes. Three factors underline the importance of a registry for these populations. First, large randomized trials of hemodynamic support, involving cardiogenic shock, are challenging to conduct...
May 2018: American Heart Journal
https://www.readbyqxmd.com/read/29733512/survival-analysis-of-adult-patients-with-all-in-mexico-city-first-report-from-the-acute-leukemia-workgroup-alwg-gtla
#2
Erick Crespo-Solis, Karla Espinosa-Bautista, Martha Alvarado-Ibarra, Etta Rozen-Fuller, Fernando Pérez-Rocha, Chantal Nava-Gómez, Maricela Ortiz-Zepeda, José Luis Álvarez-Vera, Christian Omar Ramos-Peñafiel, Luis Antonio Meillón-García, Sergio Rodríguez-Rodríguez, Alan Pomerantz-Okon, Francisco Javier Turrubiates-Hernández, Roberta Demichelis-Gómez
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the clonal expansion of hematopoietic lymphoid progenitors. With new target therapies, the survival of adults with ALL has improved in the past few decades. Unfortunately, there are no large ALL patient series in many Latin American countries. Data from the Acute Leukemia Workgroup that includes five Mexico City referral centers were used. Survival was estimated for adult patients with ALL during 2009-2015. In total, 559 adults with ALL were included...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29706443/tunnelled-central-venous-access-devices-in-small-children-a-comparison-of-open-vs-ultrasound-guided-percutaneous-insertion-in-children-weighing-ten-kilograms-or-less
#3
Liam Vierboom, Alexandre Darani, Catherine Langusch, Svs Soundappan, Jonathan Karpelowsky
PURPOSE: Ultrasound-guided (USG) percutaneous insertion of tunnelled central venous access devices (CVADs) has been shown to be safe and effective in adults. However, there have been concerns over the safety of this technique in small children. This paper analyses the safety of USG percutaneous CVAD insertion in the pediatric population weighing ten kilograms or less. METHOD: All surgically inserted CVADs for children weighing ten kilograms or less, between January 2010 and December 2015 at the Children's Hospital at Westmead were retrospectively reviewed...
April 5, 2018: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29669583/protocol-for-a-systematic-review-and-thematic-synthesis-of-patient-experiences-of-central-venous-access-devices-in-anti-cancer-treatment
#4
Caoimhe Ryan, Hannah Hesselgreaves, Olivia Wu, Jim Paul, Judith Dixon-Hughes, Jonathan G Moss
BACKGROUND: Three types of central venous access devices (CVADs)-peripherally inserted central catheters (PICCs), skin-tunnelled central catheters (Hickman-type devices), and implantable chest wall Ports (Ports)-are routinely used in the intravenous administration of anti-cancer treatment. These devices avoid the need for peripheral cannulation and allow for home delivery of treatment. Assessments of these devices have tended to focus on medical and economic factors, but there is increased interest in the importance of patient experiences and perspectives in this area...
April 18, 2018: Systematic Reviews
https://www.readbyqxmd.com/read/29611764/lenalidomide-combined-with-r-gdp-in-a-patient-with-refractory-cd5-positive-diffuse-large-b-cell-lymphoma-a-promising-response-and-review
#5
Yaping Zhang, Xinfeng Wang, Yifei Liu, Chunfeng Sun, Wenyu Shi, Hongming Huang
CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) is associated with poor survival compared with CD5-negative DLBCL. The clinical characteristics of CD5+ DLBCL are different from both CD5-negative DLBCL and other CD5+ B cell lymphomas. There is currently no promising chemotherapy for CD5+ DLBCL. Herein, we report a 49-year-old Asian male with refractory CD5+ DLBCL. He complained of aggravated abdominal pain and weight loss. Computed tomography scan revealed abdominal masses, widespread lymphadenopathy, splenomegaly, and intussusception of the ileocecal junction with bowel wall thickening...
April 3, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29577531/burden-of-illness-and-costs-among-paediatric-haemophilia-patients-with-and-without-central-venous-access-devices-treated-in-us-hospitals
#6
B Buckley, J Dreyfus, M Prasad, J Gayle, J Kendter, E Hall
INTRODUCTION: Central venous access devices (CVADs) facilitate repeated or urgent treatments for paediatric haemophilia patients, but are associated with complications. This study examined the burden of illness, healthcare utilization and costs for CVADs in a real-world hospital setting. MATERIALS AND METHODS: This study included haemophilia patients ages ≤18 years with discharges during 2006-2014 in the US Premier Healthcare Database. Haemophilia was identified using ICD-9 diagnosis codes and CVAD exposure using billing information...
March 25, 2018: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://www.readbyqxmd.com/read/29573510/arteriovenous-shunts-as-venous-access-in-children-with-haemophilia
#7
K E Thom, T Hölzenbein, N Jones, K Zwiauer, W Streif, S Gattringer, C Male
INTRODUCTION: Venous access is essential in patients with haemophilia for administration of factor concentrates. Peripheral venipuncture may be challenging, particularly in young children or during immune tolerance induction (ITI). Central venous access devices (CVADs) carry a significant risk for complications. An alternative for venous access is peripheral arteriovenous shunts (AVSs), but there is sparse documentation in the literature. The aim of this study was to document our experience with AVS over 12 years in 27 boys with severe haemophilia...
March 24, 2018: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://www.readbyqxmd.com/read/29561444/t-cell-lymphoma-with-abundant-cd20-expression-showing-a-good-response-to-rituximab-with-gemcitabine-oxiplatin-and-l-asparaginase-r-pgemox-a-case-report
#8
Yajuan Shao, Chunmei Bai, Jian Sun, Xin Gao
RATIONALE: T-cell lymphoma is a neoplasm that expresses markers of T-cell or natural killer cell (NK)-origin but not those of B-cell origin. Although B-cell lymphoma with abundant expression of T-cell markers exist, the opposite is very rare. Therefore, little is known about this subtype of lymphoma, including its treatment and prognosis. CASE REPORT: A 65-year-old man was diagnosed with T-cell lymphoma with abundant CD20 expression. He was refractory to cyclophosphamide + epirubicin + vincristine + prednisone + etoposide (CHOPE), ifosfamide + cisplatin + etoposide + dexamethasone (DICE), and hyper-cyclophosphamide + vincristine + epirubicin + dexamethasone (CVAD) chemotherapy...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29490389/minimally-invasive-versus-conventional-lvad-implantation-an-analysis-of-the-literature
#9
Kristina Wachter, Ulrich F W Franke, Christian J Rustenbach, Hardy Baumbach
This review aims to provide an overview on recent data to evaluate minimally invasive (MVAD) and conventional (CVAD) left ventricular assist device (LVAD) implantation. A comprehensive literature search of PubMed, Cochrane Library, and ClinicalTrials.gov was conducted up to April 2017. A total of 183 studies were identified; 13 studies met inclusion criteria. The review revealed a trend toward a lower rate of transfusion, and shorter time for cardiopulmonary bypass, as well as a lower 30-day mortality rate for MVAD...
February 28, 2018: Thoracic and Cardiovascular Surgeon
https://www.readbyqxmd.com/read/29489708/does-a-dedicated-lumen-for-parenteral-nutrition-administration-reduce-the-risk-of-catheter-related-bloodstream-infections-a-systematic-literature-review
#10
Nicole Clare Gavin, Elise Button, Maria Isabel Castillo, Gillian Ray-Barruel, Samantha Keogh, David J McMillan, Claire M Rickard
Guidelines recommend using single-lumen central vascular access devices (CVADs) for the administration of parenteral nutrition (PN) or lipid-based solutions, or a dedicated lumen on a multilumen CVAD. Publications reviewed by the authors reported comparative rates of catheter-related bloodstream infection (CR-BSI) in patients with CVADs who received PN through a dedicated lumen compared with those who had PN administered through multilumen CVADs. Two studies included 650 patients with 1349 CVADs. CR-BSIs were equally distributed between the 2 groups...
March 2018: Journal of Infusion Nursing: the Official Publication of the Infusion Nurses Society
https://www.readbyqxmd.com/read/29472511/development-and-implementation-of-an-antimicrobial-lock-therapy-guideline-in-a-pediatric-hospital
#11
Tracy N Zembles, Linda S Flannery, Anna R Huppler
PURPOSE: The development and implementation of an antimicrobial lock therapy guideline at a large pediatric hospital are described. SUMMARY: Central venous access devices (CVADs) are essential in the medical management of patients requiring long-term total parenteral nutrition, chemotherapy, or hemodialysis. However, the use of a CVAD carries a significant risk of the development of central line-associated bloodstream infection (CLABSI). Antimicrobial lock therapy is indicated for patients with CLABSIs who have no signs of exit site or tunnel infection and for whom catheter salvage is a goal...
March 1, 2018: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/29383863/effectiveness-of-modified-hyper-cvad-chemotherapy-regimen-in-the-treatment-of-adult-acute-lymphoblastic-leukemia-a-retrospective-experience
#12
Hasan Jalaeikhoo, Mohsen Rajaeinejad, Manoutchehr Keyhani, Mohammad Zokaasadi, Mohammad Mehdi Dehghani Firoozabadi
Several chemotherapy regimens have been developed for the treatment of acute lymphoblastic leukemia (ALL), but relapse still presents the most common obstacles to attaining long-term survival. The hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and prednisolone)/HD MTX and Ara-C (high-dose methotrexate and cytarabine) chemotherapy regimen was first started in the MD Anderson Cancer Center as an intensive regimen for adult patients with ALL. The purpose of this study was to evaluate the effectiveness of a modified hyper-CVAD protocol...
March 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29370923/the-role-of-mechanical-circulatory-support-during-percutaneous-coronary-intervention-in-patients-without-severely-depressed-left-ventricular-function
#13
Khaldoon Alaswad, Mir Babar Basir, Akshay Khandelwal, Theodore Schreiber, William Lombardi, William O'Neill
Currently, there are no data on the use of mechanical circulatory support (MCS) in patients without severely depressed left ventricular ejection fraction (LVEF) during high-risk percutaneous coronary intervention (PCI). We analyzed data from the global catheter-based ventricular assist device (cVAD) registry on the clinical use of MCS in high-risk PCI in patients without severely depressed LVEF, defined as LVEF > 35%. Patients without cardiogenic shock from the catheter-based ventricular assist device registry, who underwent elective or urgent PCI with an Impella 2...
March 15, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29368572/managing-dysfunctional-central-venous-access-devices-a-practical-approach-to-urokinase-thrombolysis
#14
Mick Kumwenda, Lisa Dougherty, Helen Spooner, Victoria Jackson, Sandip Mitra, Nicholas Inston
Tunnelled central venous access devices (CVADs) are defined as any intravenous multipurpose catheters placed within the central veins for use in haemodialysis and administration of blood products or chemotherapy in oncology and haematological conditions. Frequent complications include thrombosis and catheter-related infection, which may lead to significant adverse patient outcomes. Once thrombosis is suspected correction should be attempted empirically with thrombolytic agents. Commonly available thrombolytic agents in the UK include urokinase (Syner-Kinase) and alteplase (Cathflo)...
January 25, 2018: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/29365397/-clinical-and-bacteriological-analysis-of-lymphoid-tissue-neoplasms-patients-with-bacteria-bloodstream-infections
#15
T Y Wang, Z J Li, Q S Lin, D Su, R Lyu, S H Deng, W W Sui, M W Fu, W Y Huang, W Liu, H Liu, L G Qiu
Objective: To investigate the clinical status of lymphoid tissue neoplasms patients with bacteria bloodstream infections, bacteriology and drug susceptibility results, and provide the basis for rational clinical anti-infection option. Methods: A retrospectively analysis of clinical data and bacterial susceptibility test results of patients with bacteria bloodstream infections from September 2010 to December 2014 was conducted. Results: A total of 134 cases including 107 patients with bloodstream infections were enrolled...
December 14, 2017: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29352703/inotuzumab-ozogamicin-in-combination-with-low-intensity-chemotherapy-for-older-patients-with-philadelphia-chromosome-negative-acute-lymphoblastic-leukaemia-a-single-arm-phase-2-study
#16
Hagop Kantarjian, Farhad Ravandi, Nicholas J Short, Xuelin Huang, Nitin Jain, Koji Sasaki, Naval Daver, Naveen Pemmaraju, Joseph D Khoury, Jeffrey Jorgensen, Yesid Alvarado, Marina Konopleva, Guillermo Garcia-Manero, Tapan Kadia, Musa Yilmaz, Gautam Bortakhur, Jan Burger, Steven Kornblau, William Wierda, Courtney DiNardo, Alessandra Ferrajoli, Jovitta Jacob, Rebecca Garris, Susan O'Brien, Elias Jabbour
BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin, calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic leukaemia. We aimed to assess the activity and safety of inotuzumab ozogamicin in combination with low-intensity chemotherapy in older patients with acute lymphoblastic leukaemia. METHODS: We did a single-arm, phase 2 study at the MD Anderson Cancer Center (Houston, TX, USA). Eligible patients were aged 60 years or older and had newly diagnosed, Philadelphia chromosome-negative, acute lymphoblastic leukaemia, and an Eastern Cooperative Oncology Group performance status of 3 or lower...
February 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29323084/fibroblast-growth-factor-receptor-1-associated-myeloproliferative-neoplasm-and-t-lymphoblastic-lymphoma
#17
Gayathri Gopan, T M Anoop, N P Prakash, Rakul Nambiar, R Krishnachandran
Myeloid and lymphoid hematological malignancies with eosinophilia and abnormalities of fibroblast growth factor receptor-1 (FGFR1) result from the formation of abnormal fusion genes that encode constitutively activated tyrosine kinases. The WHO classification (2008) of hematolymphoid neoplasms recognizes a category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of FGFR1. Here, we present the case of a 30-year-old-woman who was diagnosed with T-lymphoblastic lymphoma from lymph node biopsy and myeloproliferative neoplasm with eosinophilia from bone marrow studies...
October 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29301288/use-of-pleuroperitoneal-shunt-in-chylothorax-related-to-central-line-associated-thrombosis-in-sickle-cell-disease
#18
Elizabeth Spiwak, Chad Wiesenauer, Arun Panigrahi, Ashok Raj
Central vein thrombosis as a cause of chylothorax is uncommon, and in a few cases in the literature was related to thrombotic complications of central venous access devices (CVAD). Superior vena cava (SVC) occlusion-induced chylothorax has been described in adult sickle cell disease (SCD) in a setting of chronic indwelling CVAD. There are limited reports on chylothorax induced by central venous thrombosis secondary to chronic CVAD in children with SCD. We describe an 8-year-old male patient, with a history of SCD, maintained on long term erythrocytapheresis for primary prevention of stroke, and whose clinical course was complicated by chylothorax which was successfully treated with a pleuroperitoneal shunt...
January 2, 2018: Children
https://www.readbyqxmd.com/read/29191715/vcr-cvad-induction-chemotherapy-followed-by-maintenance-rituximab-produces-durable-remissions-in-mantle-cell-lymphoma-a-wisconsin-oncology-network-study
#19
Julie E Chang, Lakeesha L Carmichael, KyungMann Kim, Christopher Peterson, David T Yang, Anne M Traynor, Jae E Werndli, Michael S Huie, Thomas A McFarland, Michael Volk, Jules Blank, Natalie S Callander, Walter L Longo, Brad S Kahl
INTRODUCTION: VcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger patients with MCL. PATIENTS AND METHODS: Patients with previously untreated MCL received VcR-CVAD induction chemotherapy for 6 cycles (21-day cycles). Patients achieving at least a partial response received rituximab consolidation (375 mg/m2  × 4 weekly doses) and MR (375 mg/m2 every 12 weeks × 20 doses)...
January 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29147847/r-hyper-cvad-versus-r-chop-cytarabine-with-high-dose-therapy-and-autologous-haematopoietic-stem-cell-support-in-fit-patients-with-mantle-cell-lymphoma-20-years-of-single-center-experience
#20
COMPARATIVE STUDY
Fabienne Widmer, Stefan Balabanov, Davide Soldini, Panagiotis Samaras, Bernhard Gerber, Markus G Manz, Jeroen S Goede
Standard of care for untreated mantle cell lymphoma (MCL) is still debated. At the University Hospital Zurich, advanced MCL in physically fit patients is treated either with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone induction followed by consolidating high-dose chemotherapy and autologous stem cell support (R-CHOP/HD-ASCT), or with rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high-dose methotrexate-cytarabine (R-hyper-CVAD/MTX-AraC) without consolidating HD-ASCT upon physicians' and patients' choice...
February 2018: Annals of Hematology
keyword
keyword
83162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"